Global Corporate Affairs Archives | Page 145 of 1087 | Be Korea-savvy

Archive by category Global Corporate Affairs

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

TEL AVIV, Israel, June 03, 2025 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% [...]

Bitget Launches Second Year of Anti-Scam Month Campaign to Fight Growing Cyber Fraud

Bitget Launches Second Year of Anti-Scam Month Campaign to Fight Growing Cyber Fraud

VICTORIA, Seychelles, June 03, 2025 (Korea Bizwire) – Bitget, the leading cryptocurrency exchange and Web3 company, has officially launched the second year of its Anti-Scam Month, a global initiative run to spread crypto security awareness. In a world where scams have become as sophisticated as the technologies meant to prevent them, Bitget is taking a cultural stand: [...]

Grow Your IB and Affiliate Business with Axi at the 2025 Money Expo Colombia

Grow Your IB and Affiliate Business with Axi at the 2025 Money Expo Colombia

SYDNEY, June 03, 2025 (Korea Bizwire) – Leading online FX and CFD broker Axi has announced that it will attend this year’s Money Expo Colombia, taking place June 25-26, 2025, in Bogota, Colombia. Event attendees will have the opportunity to explore how they can grow their IB and Affiliate business. “We invite all traders to [...]

Constellation Brands Announces Delivery of Notices of Redemption for 4.75% Senior Notes Due 2025 and 5.00% Senior Notes Due 2026

Constellation Brands Announces Delivery of Notices of Redemption for 4.75% Senior Notes Due 2025 and 5.00% Senior Notes Due 2026

ROCHESTER, N.Y., June 02, 2025 (Korea Bizwire) – Constellation Brands (NYSE: STZ), a leading beverage alcohol company, announced today that it has given notice for full redemption prior to maturity of all of its outstanding 4.75% Senior Notes due 2025 (CUSIP Number: 21036PAP3) and 5.00% Senior Notes due 2026 (CUSIP Number: 21036PBN7) (collectively, the ”notes”) to be effected [...]

Constellation Brands Closes Wine Transaction With The Wine Group to Focus on a Portfolio of Exclusively Higher-Growth, Higher-Margin Brands

Constellation Brands Closes Wine Transaction With The Wine Group to Focus on a Portfolio of Exclusively Higher-Growth, Higher-Margin Brands

Retained portfolio for Constellation includes a collection of award-winning, iconic brands, predominantly priced $15 and above and in growing segments and channels ROCHESTER, N.Y., June 02, 2025 (Korea Bizwire) – Constellation Brands (NYSE: STZ), a leading beverage alcohol company, announced today that it has closed its previously announced transaction with The Wine Group to divest1 primarily mainstream wine [...]

GBI Launches Green Globes® Data Center Campus Certification Alongside Compass Datacenters for Sustainable Digital Infrastructure

GBI Launches Green Globes® Data Center Campus Certification Alongside Compass Datacenters for Sustainable Digital Infrastructure

PORTLAND, Ore., June 02, 2025 (Korea Bizwire) – Green Building Initiative (GBI) announces the release of the Green Globes Data Center Campus Certification, tailored to the unique operational and infrastructure demands of data center campuses. The innovative offering provides data center owners and operators with a streamlined, efficient, and cost-effective way to assess and certify [...]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolio Builds on established experience and leadership in oncology and immunology [...]

Gatorade 5v5 Finals Bring Global Youth to Champions League Stage in Munich

Gatorade 5v5 Finals Bring Global Youth to Champions League Stage in Munich

MUNICH, Germany, May 31, 2025 (Korea Bizwire) – There was a palpable sense of excitement in Munich as the city prepared to host the UEFA Champions League final between PSG and Inter Milan. Fans from France and Italy – and much further afield – have been gathering in the Bavarian capital for several days. But this [...]

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research [...]

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-’749 (olanzapine) to Date

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-’749 (olanzapine) to Date

Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-’749 after more than 3,400 subcutaneous injections in study participants to date As a leader in neuroscience, Teva [...]